Skip to main content
Top
Published in: Rheumatology International 1/2020

01-01-2020 | Erythema Nodosum | Case Based Review

Digital ischemia in Behçet’s disease: case-based review

Authors: Gopika Hari, Nedaa Skeik

Published in: Rheumatology International | Issue 1/2020

Login to get access

Abstract

Behçet’s disease is a rare chronic autoimmune disease affecting primarily Middle and East Asian populations between the ages of 20 and 40 years. Behçet’s disease manifests with oral and genital mucocutaneous lesions, ocular disease, venous thrombosis, and central nervous system degradation. Treatment can be challenging and may require immunosuppressive agents and/or topical wound-care. While larger vascular involvement has been reported, digital ischemia due to small-vessel involvement has not been well described in the literature. Based on a systematic literature review, we were only able to find seven published cases of limb ischemia, none of which reported digital involvement. We present a unique case of Behçet’s disease with severe digital ischemia and ulceration caused by small-vessel involvement. The patient was managed successfully with antiplatelet, immunosuppressants, and anti-inflammatories with complete resolution of the ischemic symptoms. By focusing on small-vessel involvement and digital ischemia, we provide insight into clinical presentation and treatment for this very rare vascular manifestation of Behçet’s disease.
Literature
1.
go back to reference Yurdakul S, Hamuryudan V, Yazici H (2004) Behçet syndrome. Curr Opin Rheumatol 16:38–42CrossRef Yurdakul S, Hamuryudan V, Yazici H (2004) Behçet syndrome. Curr Opin Rheumatol 16:38–42CrossRef
2.
go back to reference Neves FS, Caldas CA, Lage LV, Goldenstein-schainberg C, Gonçalves CR (2009) Faraway from the silk route: demographic and clinical features of Behçet’s disease in 106 Brazilian patients. Clin Rheumatol 28:543–546CrossRef Neves FS, Caldas CA, Lage LV, Goldenstein-schainberg C, Gonçalves CR (2009) Faraway from the silk route: demographic and clinical features of Behçet’s disease in 106 Brazilian patients. Clin Rheumatol 28:543–546CrossRef
3.
go back to reference Calamia KT, Wilson FC, Icen M, Crowson CS, Gabriel SE, Kremers HM (2009) Epidemiology and clinical characteristics of Behçet’s disease in the US: a population-based study. Arthritis Rheum 61:600–604CrossRef Calamia KT, Wilson FC, Icen M, Crowson CS, Gabriel SE, Kremers HM (2009) Epidemiology and clinical characteristics of Behçet’s disease in the US: a population-based study. Arthritis Rheum 61:600–604CrossRef
4.
go back to reference Davatchi F, Shahram F, Chams-davatchi C et al (2012) Behcet’s disease: is there a gender influence on clinical manifestations? Int J Rheum Dis 15:306–314CrossRef Davatchi F, Shahram F, Chams-davatchi C et al (2012) Behcet’s disease: is there a gender influence on clinical manifestations? Int J Rheum Dis 15:306–314CrossRef
5.
go back to reference Poddighe D, Mukusheva Z, Dauyey K, Assylbekova M (2019) Adalimumab in the treatment of pediatric Behçet’s disease: case-based review. Rheumatol Int 39:1107–1112CrossRef Poddighe D, Mukusheva Z, Dauyey K, Assylbekova M (2019) Adalimumab in the treatment of pediatric Behçet’s disease: case-based review. Rheumatol Int 39:1107–1112CrossRef
6.
go back to reference Zaide N, Awada H (2006) Late onset Behcet’s disease. Joint Bone Spine 73:567–569CrossRef Zaide N, Awada H (2006) Late onset Behcet’s disease. Joint Bone Spine 73:567–569CrossRef
7.
go back to reference Rizzi R, Bruno S, Dammacco R (1997) Behçet’s disease: an immune-mediated vasculitis involving vessels of all sizes. Int J Clin Lab Res 27:225–232CrossRef Rizzi R, Bruno S, Dammacco R (1997) Behçet’s disease: an immune-mediated vasculitis involving vessels of all sizes. Int J Clin Lab Res 27:225–232CrossRef
8.
go back to reference Direskeneli H (2001) Behçet’s disease: infectious aetiology, new autoantigens, and HLA-B51. Ann Rheum Dis 60:996–1002CrossRef Direskeneli H (2001) Behçet’s disease: infectious aetiology, new autoantigens, and HLA-B51. Ann Rheum Dis 60:996–1002CrossRef
9.
go back to reference Esatoglu SN, Kutlubay Z, Ucar D et al (2017) Behçet’s syndrome: providing integrated care. J Multidiscip Healthc 10:309–319CrossRef Esatoglu SN, Kutlubay Z, Ucar D et al (2017) Behçet’s syndrome: providing integrated care. J Multidiscip Healthc 10:309–319CrossRef
10.
go back to reference Lee ES, Bang D, Lee S (1997) Dermatologic manifestation of Behçet’s disease. Yonsei Med J 38:380–389CrossRef Lee ES, Bang D, Lee S (1997) Dermatologic manifestation of Behçet’s disease. Yonsei Med J 38:380–389CrossRef
11.
go back to reference Tugal-tutkun I, Onal S, Altan-yaycioglu R, Huseyin-altunbas H, Urgancioglu M (2004) Uveitis in Behçet disease: an analysis of 880 patients. Am J Ophthalmol 138:373–380CrossRef Tugal-tutkun I, Onal S, Altan-yaycioglu R, Huseyin-altunbas H, Urgancioglu M (2004) Uveitis in Behçet disease: an analysis of 880 patients. Am J Ophthalmol 138:373–380CrossRef
12.
go back to reference Kötter I, Eckstein AK, Stübiger N, Zierhut M (1998) Treatment of ocular symptoms of Behçet’s disease with interferon alpha 2a: a pilot study. Br J Ophthalmol 82:488–494CrossRef Kötter I, Eckstein AK, Stübiger N, Zierhut M (1998) Treatment of ocular symptoms of Behçet’s disease with interferon alpha 2a: a pilot study. Br J Ophthalmol 82:488–494CrossRef
13.
go back to reference Hatemi G, Christensen R, Bang D et al (2018) 2018 update of the EULAR recommendations for the management of Behçet’s syndrome. Ann Rheum Dis 77:808–818PubMed Hatemi G, Christensen R, Bang D et al (2018) 2018 update of the EULAR recommendations for the management of Behçet’s syndrome. Ann Rheum Dis 77:808–818PubMed
14.
go back to reference Erkan F, Gül A, Tasali E (2001) Pulmonary manifestations of Behçet’s disease. Thorax 56:572–578CrossRef Erkan F, Gül A, Tasali E (2001) Pulmonary manifestations of Behçet’s disease. Thorax 56:572–578CrossRef
15.
go back to reference Seyahi E, Yurdakul S (2011) Behçet’s syndrome and thrombosis. Mediterr J Hematol Infect Dis 3:e2011026CrossRef Seyahi E, Yurdakul S (2011) Behçet’s syndrome and thrombosis. Mediterr J Hematol Infect Dis 3:e2011026CrossRef
16.
go back to reference Alibaz-oner F, Karadeniz A, Ylmaz S et al (2015) Behçet disease with vascular involvement: effects of different therapeutic regimens on the incidence of new relapses. Medicine (Baltimore) 94:e494CrossRef Alibaz-oner F, Karadeniz A, Ylmaz S et al (2015) Behçet disease with vascular involvement: effects of different therapeutic regimens on the incidence of new relapses. Medicine (Baltimore) 94:e494CrossRef
17.
go back to reference Seyahi E, Karaaslan H, Ugurlu S, Yazici H (2013) Fever in Behçet’s syndrome. Clin Exp Rheumatol 31:64–67PubMed Seyahi E, Karaaslan H, Ugurlu S, Yazici H (2013) Fever in Behçet’s syndrome. Clin Exp Rheumatol 31:64–67PubMed
18.
go back to reference ITR-ICBD (2014) The International Criteria for Behçet’s Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol 28:338–347CrossRef ITR-ICBD (2014) The International Criteria for Behçet’s Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol 28:338–347CrossRef
19.
go back to reference Saip S, Akman-demir G, Siva A (2014) Neuro-Behçet syndrome. Handb Clin Neurol 121:1703–1723CrossRef Saip S, Akman-demir G, Siva A (2014) Neuro-Behçet syndrome. Handb Clin Neurol 121:1703–1723CrossRef
20.
go back to reference Mat C, Yurdakul S, Sevim A, Özyazgan Y, Tüzün Y (2013) Behçet’s syndrome: facts and controversies. Clin Dermatol 31:352–361CrossRef Mat C, Yurdakul S, Sevim A, Özyazgan Y, Tüzün Y (2013) Behçet’s syndrome: facts and controversies. Clin Dermatol 31:352–361CrossRef
21.
go back to reference Saadoun D, Wechsler B, Desseaux K et al (2010) Mortality in Behcet’s disease. Arthritis Rheum 62:2806–2812CrossRef Saadoun D, Wechsler B, Desseaux K et al (2010) Mortality in Behcet’s disease. Arthritis Rheum 62:2806–2812CrossRef
22.
go back to reference Elsharawy MA, Hassan KA, Al-awami M, Al-mulhim FA (2004) Dramatic vascular course of Behcet’s disease. Saudi Med J 25:2013–2015PubMed Elsharawy MA, Hassan KA, Al-awami M, Al-mulhim FA (2004) Dramatic vascular course of Behcet’s disease. Saudi Med J 25:2013–2015PubMed
23.
go back to reference Iscan ZH, Vural KM, Bayazit M (2005) Compelling nature of arterial manifestations in Behcet disease. J Vasc Surg 41:53–58CrossRef Iscan ZH, Vural KM, Bayazit M (2005) Compelling nature of arterial manifestations in Behcet disease. J Vasc Surg 41:53–58CrossRef
24.
go back to reference Akiyama K, Hirota J, Ohkado A, Shiina Y (1998) Multivarious clinical manifestations of multiple pseudoaneurysms in Behçet’s disease. J Cardiovasc Surg (Torino) 39:175–178 Akiyama K, Hirota J, Ohkado A, Shiina Y (1998) Multivarious clinical manifestations of multiple pseudoaneurysms in Behçet’s disease. J Cardiovasc Surg (Torino) 39:175–178
25.
go back to reference Sechas MN, Liapis CD, Gougoulakis AG, Mandrekas DP, Fotiadis CI, Vaiopoulos GA (1989) Vascular manifestations of Behçet’s disease. Int Angiol 8:145–150PubMed Sechas MN, Liapis CD, Gougoulakis AG, Mandrekas DP, Fotiadis CI, Vaiopoulos GA (1989) Vascular manifestations of Behçet’s disease. Int Angiol 8:145–150PubMed
Metadata
Title
Digital ischemia in Behçet’s disease: case-based review
Authors
Gopika Hari
Nedaa Skeik
Publication date
01-01-2020
Publisher
Springer Berlin Heidelberg
Published in
Rheumatology International / Issue 1/2020
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-019-04452-z

Other articles of this Issue 1/2020

Rheumatology International 1/2020 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.